AMLX - Amylyx Pharmaceuticals, Inc.

14.11
-1.190   -8.434%

Share volume: 1,356,676
Last Updated: 03-03-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$15.30
-1.19
-0.08%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
47%
Profitability 53%
Dept financing 21%
Liquidity 75%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-6.99%
1 Month
1.66%
3 Months
-2.62%
6 Months
41.81%
1 Year
368.77%
2 Year
-26.28%
Key data
Stock price
$14.11
P/E Ratio 
0.00
DAY RANGE
$13.75 - $15.70
EPS 
-$2.40
52 WEEK RANGE
$3.11 - $17.49
52 WEEK CHANGE
$319.94
MARKET CAP 
1.212 B
YIELD 
N/A
SHARES OUTSTANDING 
109.820 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-07-2025
BETA 
2.80
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,162,288
AVERAGE 30 VOLUME 
$902,215
Company detail
CEO: Joshua B. Cohen
Region: US
Website: amylyx.com
Employees: 200
IPO year: 2022
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Amylyx Pharmaceuticals, Inc. develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product candidature includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid.

Recent news